A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

被引：1
|
作者：
Daver, Naval [1 ]
Dao, Kim-Hien [2 ]
Assad, Albert [3 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Incyte Corp, Wilmington, DE USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-028
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
    Coleman, Morton
    Belada, David
    Casasnovas, Rene-Olivier
    Gressin, Remy
    Lee, Hui-Peng
    Mehta, Amitkumar
    Munoz, Javier
    Verhoef, Gregor
    Corrado, Claudia
    DeMarini, Douglas James
    Zhao, Wanying
    Chen, Xuejun
    Fay, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly
    Palandri, Francesca
    Polverelli, Nicola
    Breccia, Massimo
    Nicolino, Barbara
    Vitolo, Umberto
    Alimena, Giuliana
    Cavo, Michele
    Vianelli, Nicola
    Benevolo, Giulia
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 160 - 162
  • [33] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit K.
    Ali, Haris
    Wang, Eunice
    Gerds, Aaron T.
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen T.
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2022, 140
  • [34] Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study
    Sotiropoulos, Damianos
    Papadopoulos, Vassilios
    Dimou, Maria
    Kyriakou, Despoina
    Papaioannou, George
    Karavalakis, George
    Papadakis, Emmanuel
    Palasopoulou, Maria
    Banti, Anastasia
    Kourelis, Taxiarchis
    Kouraklis, Alexandra
    Marinakis, Theodoros
    Viniou, Nora-Athina
    Hatzimichael, Eleftheria
    Vasilatou, Diamantina
    Vassilopoulos, George
    Panayiotidis, Panayiotis
    Anagnostopoulos, Achilles
    BLOOD, 2015, 126 (23)
  • [35] Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Harrison, Claire N.
    Hasselbalch, Hans
    Pieri, Lisa
    Koschmieder, Steffen
    Cervantes, Francisco
    Bao, Weichao
    Kalambakas, Stacey
    Atienza, Edric
    Gopalakrishna, Prashanth
    Heidel, Florian H.
    BLOOD, 2015, 126 (23)
  • [36] Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis
    Mikkelsen, Stine Ulrik
    Kjaer, Lasse
    Bjorn, Mads Emil
    Knudsen, Trine Alma
    Sorensen, Anders Lindholm
    Andersen, Christen Bertel Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Pallisgaard, Niels
    Thomassen, Mads
    Skov, Vibe
    Hasselbalch, Hans Carl
    CANCER MEDICINE, 2018, 7 (08): : 3571 - 3581
  • [37] Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3626 - 3626
  • [38] Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)
    Kirito, Keita
    Komatsu, Norio
    Shimoda, Kazuya
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    BLOOD, 2015, 126 (23)
  • [39] The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
    Duan, Minghui
    Ma, Lan
    Wu, Qiuling
    Liang, Hong
    Wang, Wei
    Wu, Shaoling
    Mu, Lijun
    Lin, Hai
    Zhou, Hebing
    Shi, Hong-Xia
    Wang, Jinghua
    Jing, Hongmei
    BLOOD, 2023, 142
  • [40] Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
    Harrison, Claire N.
    Garcia, Jacqueline S.
    Mesa, Ruben A.
    Somervaille, Tim C. P.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Holes, Leanne
    Jia, Jia
    Harb, Jason
    Hutti, Jessica
    Prchal, Josef T.
    BLOOD, 2019, 134
12345